At present, many patients with advanced tumors are facing the dilemma of no medicine available.
common drug resistance, no mutation target, no drug matching, no drug effect, chemotherapy intolerant , etc. are often the reasons why there is no drug available in patients with advanced tumors.
has no medicine available, which is the most worrying situation for many patients with advanced tumors. So, are there other possible ways to save patients in a dilemma of no medicine available?
The answer is yes. For patients who have no medicine available, the following three methods are expected to break through the dilemma.
Method 1: Clinical trial
With the development of medical technology, clinical trials covering various cancer types and multiple treatment methods have gradually been recruited for tumor patients, and many clinical trials have recruited patients with advanced tumors who have no drugs available.
Some patients may think that clinical trials are treating patients as "villains", but in fact this is not the case.
clinical trials are mainly through humans (patients or healthy subjects) to test , and discover or verify the clinical medicine , pharmacological , pharmacological , pharmacological effects and adverse reactions of a certain experimental drug, thereby determining the efficacy and safety of the drug.
, but clinical trials are not without safety guarantees. clinical trials must pass the approval of the national drug regulatory department before they can officially launch . And before conducting clinical trials, relevant researchers have conducted a large number of trials on cells and animals, proving that the expected benefits outweigh the risks. Therefore, the saying "little mouse" is not true.
It is reported that after a elderly male advanced gastric cancer patient who failed to recurrence treatment joined the clinical trial of solid tumor CAR-T therapy, the tumor shrank significantly and his life was significantly prolonged.
It can be seen that clinical trials are new hope for patients with advanced tumors without drugs, and clinical trials are free . Therefore, while bringing patients relatively large new drug opportunities, it can also reduce the family's financial burden to a certain extent.
, but it should be noted that when screening and registering for clinical trials, you should consult a professional doctor to register for clinical trials that are suitable and have relatively high treatment benefits.
Generally speaking, clinical trials are divided into phase I, II, and III, among which III clinical trials are better than phase I and phase II clinical trials. Patients with advanced tumors who have no medication available can generally participate in phase I or phase II clinical trials.
Method 2: NGS gene sequencing
As we all know, tumors are a genetic disease, and gene mutations play an important role in the occurrence and development of tumors. If the corresponding mutant gene can be found and targeted medication can be used, the tumor condition can be controlled.
Although some tumor patients who have no drugs have been tested for genes before, it may be that due to problems such as incomplete detection of and the detection company's technical restrictions on , gene mutations with guiding drug use were not detected, thus losing the opportunity to use the drug.
Therefore, for patients with advanced tumors who have no drugs available, NGS gene sequencing may lead to new drug use opportunities.
NGS gene sequencing is also known as massive parallel sequencing, high-throughput sequencing technology . Only one detection is performed using tissue sections, and accurate and comprehensive gene analysis detection technology can be obtained.
NGS gene sequencing is low cost, high accuracy, and fast detection. It can detect rare mutation targets, which is of great significance to patients' treatment. And European Society of Medical Oncology (ESMO) recommends that tumor patients should consider NGS gene sequencing.
It is reported that a patient with advanced intrahepatic cholangiocarcinoma who had multiple systemic metastasis, multiline chemotherapy and targeting ineffective targets began to develop malignant liquid and severe fatigue. Just when the patient was discouraged, the results of NGS gene testing brought hope to the patient. The
test results found that there was a rare FGFR fusion in the patient. The drug targeting this target, erdatinib , so the patient participated in the clinical trial of erdatinib. After treatment, the tumor improved significantly, the patient's weight increased, and his survival was significantly extended.
It can be seen that NGS gene sequencing can also bring new hope for medication to patients with advanced tumors who have no drugs available.
But it should be noted that we should find a reliable gene detection company to conduct NGS gene sequencing, so as not to detect mutant genes due to technical limitations and miss the opportunity to use drugs.
Method 3: Drug sensitivity test—PDX model
PDX model, also known as the human tumor xenograft model , is a "private customized" and individualized tumor animal model.
PDX model is a new tumor model established by inoculating the patient's tumor tissue in mice with immunodeficiency , thereby establishing . Tumor cells that are successfully inoculated will grow in mice. It can be observed by taking medication to mice to see which drugs are effective against tumor cells.
In layman's terms, the PDX model obtains live tumor tissue from a part of advanced tumor patients through puncture or resection, and inoculates live tumor tissue into dozens of mice with immunodeficiency. After the inoculation is successful, the tumor tissue will grow in the mice. Therefore, mice that were successfully vaccinated can be used to screen various chemotherapy drugs and targeted drugs to determine drugs that are effective for tumors.
If the drug can effectively kill transplanted tumor cells in mice, then patients can consider using this drug to treat the tumor under the guidance of a doctor.
But it should be noted that establishing a PDX model is expensive, and it takes a long time to transplant and screen . And because has tumor heterogeneity , it cannot guarantee that drugs that can kill tumor cells in mice will definitely be effective in the human body.
Nevertheless, the PDX model is also a glimmer of hope for patients with advanced tumors without drugs.
In summary, for patients with advanced tumors who have no drugs available, they can consider participating in clinical trials through , conducting NGS gene sequencing, and establishing a PDX model . Based on factors such as benefit, economy and time, it is generally recommended that patients with advanced tumors who have no medication available should be given priority in participating in appropriate clinical trials.
